LifeMD Launches NavaMD

LifeMD, Inc., a leading direct-to-patient telehealth company, today announced the successful launch of NavaMD™.

LifeMD notes the NavaMD website went live at the end of the first quarter of fiscal 2021 and is the Company’s personalized tele-dermatology brand and clinic, offering services to patients across all 50 states.

Justin Schreiber, Chairman and CEO commented, “We are pleased to bring the NavaMD brand to life in 2021, as this will be LifeMD’s third successful brand launch in four years. We are an early mover in the $40 billion-dollar high growth direct-to-patient tele-dermatology space and are well-positioned to grow market share. By empowering patients seeking telehealth services, we feel that LifeMD is best positioned to actively bring about a sea change in both the convenience and accessibility by which patients receive personalized services and medications when needed. As such, we remain focused on refining customer acquisition strategies and building a de-risked brand portfolio that addresses low risk, massively underpenetrated and addressable markets such as the NavaMD clinical skincare offering.”

“By focusing on fast growing, therapeutic areas with high unmet needs, whose treatments are proven to be safe, we are creating the best runway for unrivaled growth in telehealth customer acquisition, recurring revenues and return on shareholder value,” mentioned Stefan Galluppi, Chief Technology Officer.

NavaMD’s services will be available to any patient seeking dermatology services. Service offerings include the diagnosis and treatment of prevalent skin conditions such as acne, rosacea, hyperpigmentation, signs of aging, and other prevalent skin conditions.

NavaMD’s customer acquisition strategy will be primarily set to growing its female customer base, fully supported by best-in-class direct response marketing, social media, and influencer campaigns.

Online medical treatment and services will be rendered through LifeMD’s network of U.S. licensed physicians, pharmacies, and, if appropriate, prescription oral and compounded topical medications to treat many common dermatological conditions.

In addition to the brand’s telemedicine offerings, NavaMD’s proprietary products leverage intellectual property and proprietary formulations licensed from Restorsea, a leading medical grade skincare technology platform. NavaMD is the first external provider to offer Restorsea’s patented medical-grade over-the-counter products for treating these prevalent skin conditions.

Like other LifeMD brands, NavaMD tele-dermatology services is highly personalized, powered by a proprietary technology stack. The engagement with patients is seamless and is driven by a simple three-step customer journey consisting of:

  1. Completing a free consultation: whereby a questionnaire and patient photo is submitted for review.
  2. Getting prescribed a custom formulated treatment regimen: NavaMD’s licensed U.S. doctors, and clinicians then work to design a custom prescription skincare treatment. A quick and convenient checkout process powered by LifeMD’s telehealth platform fills a prescription.
  3. The patient receives a personalized treatment by mail: LifeMD’s pharmacy services prepares and delivers a customer’s custom prescription treatment on a monthly recurring basis or as often as needed.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version